Literature DB >> 16127464

Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans.

Ana Luiza Maia1, Brian W Kim, Stephen A Huang, John W Harney, P Reed Larsen.   

Abstract

The relative roles of the types 1 and 2 iodothyronine deiodinases (D1 and D2) in extrathyroidal 3,5,3'-triiodothyronine (T3) production in humans are unknown. We calculated the rate of thyroxine (T4) to T3 conversion by intact cells transiently expressing D1 or D2 at low (2 pM), normal (20 pM), and high (200 pM) free T4 concentrations. Deiodinase activities were then assayed in cell sonicates. The ratio of T3 production in cell sonicates (catalytic efficiency) was multiplied by the tissue activities reported in human liver (D1) and skeletal muscle (D2). From these calculations, we predict that in euthyroid humans, D2-generated T3 is 29 nmol/d, while that of D1-generated T3 is 15 nmol/d, from these major deiodinase-expressing tissues. The total estimated extrathyroidal T3 production, 44 nmol/d, is in close agreement with the 40 nmol T3/d based on previous kinetic studies. D2-generated T3 production accounts for approximately 71% of the peripheral T3 production in hypothyroidism, but D1 for approximately 67% in thyrotoxic patients. We also show that the intracellular D2-generated T3 has a greater effect on T3-dependent gene transcription than that from D1, which indicates that generation of nuclear T3 is an intrinsic property of the D2 protein. We suggest that impairment of D2-generated T3 is the major cause of the reduced T3 production in the euthyroid sick syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127464      PMCID: PMC1190373          DOI: 10.1172/JCI25083

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation.

Authors:  B Gereben; C Goncalves; J W Harney; P R Larsen; A C Bianco
Journal:  Mol Endocrinol       Date:  2000-11

2.  In vivo dimerization of types 1, 2, and 3 iodothyronine selenodeiodinases.

Authors:  Cyntia Curcio-Morelli; Balazs Gereben; Ann Marie Zavacki; Brian W Kim; Stephen Huang; John W Harney; P Reed Larsen; Antonio C Bianco
Journal:  Endocrinology       Date:  2003-03       Impact factor: 4.736

3.  The iodothyronine selenodeiodinases are thioredoxin-fold family proteins containing a glycoside hydrolase clan GH-A-like structure.

Authors:  Isabelle Callebaut; Cyntia Curcio-Morelli; Jean-P Mornon; Balazs Gereben; Christoph Buettner; Stephen Huang; Bertrand Castro; Tatiana L Fonseca; John W Harney; P Reed Larsen; Antonio C Bianco
Journal:  J Biol Chem       Date:  2003-07-07       Impact factor: 5.157

4.  Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes.

Authors:  Munira Baqui; Diego Botero; Balazs Gereben; Cyntia Curcio; John W Harney; Domenico Salvatore; Kenji Sorimachi; P Reed Larsen; Antonio C Bianco
Journal:  J Biol Chem       Date:  2002-11-04       Impact factor: 5.157

Review 5.  Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases.

Authors:  Antonio C Bianco; Domenico Salvatore; Balázs Gereben; Marla J Berry; P Reed Larsen
Journal:  Endocr Rev       Date:  2002-02       Impact factor: 19.871

6.  The role of selenocysteine 133 in catalysis by the human type 2 iodothyronine deiodinase.

Authors:  C Buettner; J W Harney; P R Larsen
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

7.  The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus.

Authors:  Luis Henrique Canani; Clarissa Capp; José Miguel Dora; Erika L Souza Meyer; Márcia S Wagner; John W Harney; P Reed Larsen; Jorge L Gross; Antonio C Bianco; Ana Luiza Maia
Journal:  J Clin Endocrinol Metab       Date:  2005-03-29       Impact factor: 5.958

8.  The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line.

Authors:  C Curcio; M M Baqui; D Salvatore; B H Rihn; S Mohr; J W Harney; P R Larsen; A C Bianco
Journal:  J Biol Chem       Date:  2001-06-25       Impact factor: 5.157

9.  Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients.

Authors:  Robin P Peeters; Pieter J Wouters; Ellen Kaptein; Hans van Toor; Theo J Visser; Greet Van den Berghe
Journal:  J Clin Endocrinol Metab       Date:  2003-07       Impact factor: 5.958

10.  Direct immunoassay of triiodothyronine in human serum.

Authors:  P R Larsen
Journal:  J Clin Invest       Date:  1972-08       Impact factor: 14.808

View more
  92 in total

1.  Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment.

Authors:  Matthew L Rosene; Gábor Wittmann; Rafael Arrojo e Drigo; Praful S Singru; Ronald M Lechan; Antonio C Bianco
Journal:  Endocrinology       Date:  2010-10-06       Impact factor: 4.736

2.  Association analyses of variants in the DIO2 gene with early-onset type 2 diabetes mellitus in Pima Indians.

Authors:  Saraswathy Nair; Yunhua Li Muller; Emilio Ortega; Sayuko Kobes; Clifton Bogardus; Leslie J Baier
Journal:  Thyroid       Date:  2011-12-05       Impact factor: 6.568

3.  The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients.

Authors:  Francesco S Celi; Marina Zemskova; Joyce D Linderman; Nabeel I Babar; Monica C Skarulis; Gyorgy Csako; Robert Wesley; Rene Costello; Scott R Penzak; Frank Pucino
Journal:  Clin Endocrinol (Oxf)       Date:  2010-05       Impact factor: 3.478

4.  The -258A/G (SNP rs12885300) polymorphism of the human type 2 deiodinase gene is associated with a shift in the pattern of secretion of thyroid hormones following a TRH-induced acute rise in TSH.

Authors:  Maya Y Peltsverger; Peter W Butler; Anna Teresa Alberobello; Sheila Smith; Yanina Guevara; Ornella M Dubaz; Javier A Luzon; Joyce Linderman; Francesco S Celi
Journal:  Eur J Endocrinol       Date:  2012-02-03       Impact factor: 6.664

5.  Regulation of thyroid hormone activation via the liver X-receptor/retinoid X-receptor pathway.

Authors:  Marcelo A Christoffolete; Márton Doleschall; Péter Egri; Zsolt Liposits; Ann Marie Zavacki; Antonio C Bianco; Balázs Gereben
Journal:  J Endocrinol       Date:  2010-02-22       Impact factor: 4.286

6.  The role of type 1 and type 2 5'-deiodinase in the pathophysiology of the 3,5,3'-triiodothyronine toxicosis of McCune-Albright syndrome.

Authors:  Francesco S Celi; Giuseppe Coppotelli; Aaron Chidakel; Marilyn Kelly; Beth A Brillante; Thomas Shawker; Natasha Cherman; Penelope P Feuillan; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2008-03-18       Impact factor: 5.958

7.  Activation of thyroid hormone is transcriptionally regulated by epidermal growth factor in human placenta-derived JEG3 cells.

Authors:  Gianluca Canettieri; Antonella Franchi; Michele Della Guardia; Ianessa Morantte; Maria Giulia Santaguida; John W Harney; P Reed Larsen; Marco Centanni
Journal:  Endocrinology       Date:  2007-11-08       Impact factor: 4.736

Review 8.  Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders.

Authors:  Bernadette Biondi; George J Kahaly; R Paul Robertson
Journal:  Endocr Rev       Date:  2019-06-01       Impact factor: 19.871

Review 9.  Nonthyroidal illness syndrome in children.

Authors:  Seth D Marks
Journal:  Endocrine       Date:  2009-09-25       Impact factor: 3.633

10.  Substitution of serine for proline in the active center of type 2 iodothyronine deiodinase substantially alters its in vitro biochemical properties with dithiothreitol but not its function in intact cells.

Authors:  Iuri Martin Goemann; Balázs Gereben; John W Harney; Bo Zhu; Ana Luiza Maia; P Reed Larsen
Journal:  Endocrinology       Date:  2009-12-04       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.